The Rice Angel Network will now be powered by Cannon Ventures. Photo courtesy of Rice University

In an effort to better connect Houston entrepreneurs with angel funds, the Rice Angel Network and Cannon Ventures have formed a new partnership. RAN will now be powered by Cannon Ventures, the investment arm of The Cannon, a West Houston coworking space.

RAN is already located in The Cannon, according to its website, but the new arrangement will allow RAN to leverage The Cannon's programming, events, resources, and community as it continues to serve its alumni network.

In December, the two entities have partnered up in the past for the Houston Investor Network Alliance, a collaboration where participating investors can partner up to co-invest in startups, co-host investor events, and share opportunities. According to the release, this new partnership "takes this a step further" to team up to provide early-stage investment.

"The mission is simple," says Lawson Gow, CEO and founder of Cannon Ventures and The Cannon, in a release. "We want to bring Houston's startup ecosystem the access to capital that they need to thrive here in Houston."

Gow, who is the son of InnovationMap's parent company's CEO, started Cannon Ventures almost a year ago. He's a Rice alumnus, as is Kyle Fletcher, the managing partner of Rice Angel Network.

"Houston is one of the largest cities in the US, yet our efforts to bring capital to startups has been done only in pockets throughout the city," Fletcher says in the release. "We are better together than we are separate."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.